2 results
Approved WMOPending
Primary Objective:The objective of this pilot study is to determine whether the observed AP pharmacokinetic profiles in plasma of CABG patients in the APPIRED study can be confirmed in the CABG patients under a non-aprotinin regime.
Approved WMOPending
Primary objective:- To evaluate the efficacy of caplacizumab in combination with immunosuppressive therapy (IST) without therapeutic plasma exchange (TPE) inadults with immune mediated thrombotic thrombocytopenic purpura (iTTP)Secondary objectives:…